Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
April 26, 2018
Spago Nanomedical

Spago Nanomedical participates in EU NANO2ALL project

Spago Nanomedical participates in EU NANO2ALL project

-
Spago Nanomedical
-
April 26, 2018

Spago Nanomedical CSO Oskar Axelsson recently participated in “BUILDING RESPONSIVENESS”, a multi-stakeholder dialogue event arranged under the umbrella of the EU funded project NANO2ALL, at the European Commission in Brussels.

The workshop aimed at formulating a clear set of practical recommendations for the EU and others involved in the EU-level governance of nanotechnology research and innovation on how to make the European nanotechnological development better at taking into account societal needs and improve its governance.

The overall aim of the EU project NANO2ALL is to “enhance societal engagement in nanotechnology research and innovation” with an aspiration to “contribute to nanotechnologies that are societally acceptable, desirable and sustainable”.

For further information, contact Oskar Axelsson, oskar.axelsson@spagonanomedical.se

Spago Nanomedical develops nanomaterials for improved cancer diagnostics and treatment
Last updated:
April 26, 2018

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail

Spago Nanomedical CSO Oskar Axelsson recently participated in “BUILDING RESPONSIVENESS”, a multi-stakeholder dialogue event arranged under the umbrella of the EU funded project NANO2ALL, at the European Commission in Brussels.

The workshop aimed at formulating a clear set of practical recommendations for the EU and others involved in the EU-level governance of nanotechnology research and innovation on how to make the European nanotechnological development better at taking into account societal needs and improve its governance.

The overall aim of the EU project NANO2ALL is to “enhance societal engagement in nanotechnology research and innovation” with an aspiration to “contribute to nanotechnologies that are societally acceptable, desirable and sustainable”.

For further information, contact Oskar Axelsson, oskar.axelsson@spagonanomedical.se

Spago Nanomedical develops nanomaterials for improved cancer diagnostics and treatment
Last updated:
April 26, 2018

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail